Message From The Chair: Why Attend The 2023 ISPE Biotechnology Conference
The Biopharmaceutical industry continues to grow and deliver life-changing medicines to patients as evidenced by the number of drug approvals by the FDA year after year. In 2022 alone CDER approved 37 novel drugs, either as new molecular entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic biological products under Biologics License Applications (BLAs). This has all been achieved despite the disruptive influences experienced across all supply chain networks. Innovation in digital, sustainability, agile manufacturing concepts, and the application of new technologies have been key enablers and we continue to see growth and development in all these areas.